Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study
- PMID: 23711088
- DOI: 10.1111/joim.12093
Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study
Abstract
Objective: To investigate whether psoriasis is affected by the use of serotonin reuptake inhibitors (SSRIs).
Design: A population-based cohort study.
Setting: The general adult population with plaque psoriasis in Sweden between 1997 and 2006.
Subjects: A total of 69 830 patients with plaque psoriasis were identified in the National Patient Register. Whether study subjects were exposed to SSRIs was identified through the Swedish Prescribed Drug Register. The SSRI-exposed subjects (n = 1282) had a prescription for SSRIs dispensed twice during 6 months at a Swedish pharmacy between 1 July 2006 and 1 April 2008, with a wash-out period of 1 year or longer. The reference subjects (n = 1282), who were not exposed to SSRIs, were matched for age, county of residence, sex, psoriasis severity and seasonal variation.
Main outcome measure: Change in psoriasis severity defined by switching between nonsystemic and systemic psoriasis treatments 6 months after exposure to SSRIs.
Results: The risk of switching from nonsystemic to systemic psoriasis treatments was significantly decreased in the SSRI-exposed group (odds ratio 0.44, 95% confidence interval 0.28-0.68).
Conclusion: SSRI use in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment.
Keywords: cohort study; psoriasis; serotonin reuptake inhibitors.
© 2013 The Association for the Publication of the Journal of Internal Medicine.
Similar articles
-
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.Cochrane Database Syst Rev. 2015 Apr 1;4(4):CD002919. doi: 10.1002/14651858.CD002919.pub3. Cochrane Database Syst Rev. 2015. PMID: 25829028 Free PMC article. Review.
-
Association of selective serotonin re-uptake inhibitor (SSRI) treatment with acute substance misuse outcomes.Addiction. 2022 Jan;117(1):234-242. doi: 10.1111/add.15625. Epub 2021 Jul 12. Addiction. 2022. PMID: 34185347
-
Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.BMJ. 2015 Apr 17;350:h1798. doi: 10.1136/bmj.h1798. BMJ. 2015. PMID: 25888213 Free PMC article.
-
Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: a Swedish population-based case-control study.J Clin Psychopharmacol. 2012 Jun;32(3):336-40. doi: 10.1097/JCP.0b013e318253d71a. J Clin Psychopharmacol. 2012. PMID: 22544014
-
Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.Am J Gastroenterol. 2014 Jun;109(6):811-9. doi: 10.1038/ajg.2014.82. Epub 2014 Apr 29. Am J Gastroenterol. 2014. PMID: 24777151 Review.
Cited by
-
Serum 5-Hydroxytryptamine is Related to Psoriasis Severity in Patients with Comorbid Anxiety or Depression.Acta Derm Venereol. 2021 Aug 16;101(8):adv00514. doi: 10.2340/00015555-3857. Acta Derm Venereol. 2021. PMID: 34184067 Free PMC article. No abstract available.
-
The Brain-Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System.Cells. 2020 Mar 26;9(4):796. doi: 10.3390/cells9040796. Cells. 2020. PMID: 32224981 Free PMC article. Review.
-
Platelets Aggregate With Neutrophils and Promote Skin Pathology in Psoriasis.Front Immunol. 2019 Aug 16;10:1867. doi: 10.3389/fimmu.2019.01867. eCollection 2019. Front Immunol. 2019. PMID: 31474979 Free PMC article.
-
The vicious cycle of itch and anxiety.Neurosci Biobehav Rev. 2018 Apr;87:17-26. doi: 10.1016/j.neubiorev.2018.01.009. Epub 2018 Jan 31. Neurosci Biobehav Rev. 2018. PMID: 29374516 Free PMC article. Review.
-
Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases.Front Immunol. 2020 Feb 11;11:186. doi: 10.3389/fimmu.2020.00186. eCollection 2020. Front Immunol. 2020. PMID: 32117308 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
